KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Equity Average (2016 - 2026)

Biogen has reported Equity Average over the past 18 years, most recently at $18.5 billion for Q1 2026.

  • For Q1 2026, Equity Average rose 9.54% year-over-year to $18.5 billion; the TTM value through Mar 2026 reached $18.5 billion, up 9.54%, while the annual FY2025 figure was $17.5 billion, 10.97% up from the prior year.
  • Equity Average for Q1 2026 was $18.5 billion at Biogen, up from $9.2 billion in the prior quarter.
  • Over five years, Equity Average peaked at $18.5 billion in Q1 2026 and troughed at $8.8 billion in Q3 2025.
  • A 5-year average of $14.0 billion and a median of $14.5 billion in 2023 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: rose 22.52% in 2023 and later plummeted 45.16% in 2025.
  • Year by year, Equity Average stood at $13.1 billion in 2022, then rose by 11.94% to $14.6 billion in 2023, then rose by 12.96% to $16.5 billion in 2024, then plummeted by 44.65% to $9.2 billion in 2025, then surged by 101.59% to $18.5 billion in 2026.
  • Business Quant data shows Equity Average for BIIB at $18.5 billion in Q1 2026, $9.2 billion in Q4 2025, and $8.8 billion in Q3 2025.